164 related articles for article (PubMed ID: 38476765)
1. MiR-200c reprograms fibroblasts to recapitulate the phenotype of CAFs in breast cancer progression.
Lin Z; Roche ME; Díaz-Barros V; Domingo-Vidal M; Whitaker-Menezes D; Tuluc M; Uppal G; Caro J; Curry JM; Martinez-Outschoorn U
Cell Stress; 2024; 8():1-20. PubMed ID: 38476765
[TBL] [Abstract][Full Text] [Related]
2. Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells.
Si L; Jiang F; Li Y; Ye X; Mu J; Wang X; Ning S; Hu C; Li Z
Mol Carcinog; 2015 Sep; 54(9):859-69. PubMed ID: 24729530
[TBL] [Abstract][Full Text] [Related]
3. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs).
Lappano R; Talia M; Cirillo F; Rigiracciolo DC; Scordamaglia D; Guzzi R; Miglietta AM; De Francesco EM; Belfiore A; Sims AH; Maggiolini M
J Exp Clin Cancer Res; 2020 Aug; 39(1):153. PubMed ID: 32778144
[TBL] [Abstract][Full Text] [Related]
4. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer.
Hu JL; Wang W; Lan XL; Zeng ZC; Liang YS; Yan YR; Song FY; Wang FF; Zhu XH; Liao WJ; Liao WT; Ding YQ; Liang L
Mol Cancer; 2019 May; 18(1):91. PubMed ID: 31064356
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-181d-5p-Containing Exosomes Derived from CAFs Promote EMT by Regulating CDX2/HOXA5 in Breast Cancer.
Wang H; Wei H; Wang J; Li L; Chen A; Li Z
Mol Ther Nucleic Acids; 2020 Mar; 19():654-667. PubMed ID: 31955007
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.
Damiano V; Brisotto G; Borgna S; di Gennaro A; Armellin M; Perin T; Guardascione M; Maestro R; Santarosa M
Genes Chromosomes Cancer; 2017 Feb; 56(2):147-158. PubMed ID: 27717206
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling.
Koo T; Cho BJ; Kim DH; Park JM; Choi EJ; Kim HH; Lee DJ; Kim IA
Oncotarget; 2017 Sep; 8(39):65457-65468. PubMed ID: 29029445
[TBL] [Abstract][Full Text] [Related]
8. [Dectection and analysis of miRNA expression in breast cancer-associated fibroblasts].
Zeng Z; Hu P; Tang X; Zhang H; Du Y; Wen S; Liu M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Oct; 30(10):1071-5. PubMed ID: 25270211
[TBL] [Abstract][Full Text] [Related]
9. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
Jiang B; Xiao S; Zhang S; Xiao F
J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer.
Deng K; Zou F; Xu J; Xu D; Luo Z
Mol Carcinog; 2024 Mar; 63(3):524-537. PubMed ID: 38197482
[TBL] [Abstract][Full Text] [Related]
11. miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes.
Perdigão-Henriques R; Petrocca F; Altschuler G; Thomas MP; Le MT; Tan SM; Hide W; Lieberman J
Oncogene; 2016 Jan; 35(2):158-72. PubMed ID: 25798844
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer.
Chatterjee A; Jana S; Chatterjee S; Wastall LM; Mandal G; Nargis N; Roy H; Hughes TA; Bhattacharyya A
Br J Cancer; 2019 Oct; 121(8):679-689. PubMed ID: 31481734
[TBL] [Abstract][Full Text] [Related]
13. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.
Mutlu M; Raza U; Saatci Ö; Eyüpoğlu E; Yurdusev E; Şahin Ö
J Mol Med (Berl); 2016 Jun; 94(6):629-44. PubMed ID: 27094812
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT).
Pan Q; Meng L; Ye J; Wei X; Shang Y; Tian Y; He Y; Peng Z; Chen L; Chen W; Bian X; Wang R
Cancer Lett; 2017 Apr; 392():26-38. PubMed ID: 28163188
[TBL] [Abstract][Full Text] [Related]
15. miR-200c dampens cancer cell migration via regulation of protein kinase A subunits.
Sigloch FC; Burk UC; Biniossek ML; Brabletz T; Schilling O
Oncotarget; 2015 Sep; 6(27):23874-89. PubMed ID: 26203557
[TBL] [Abstract][Full Text] [Related]
16. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells.
Vrba L; Jensen TJ; Garbe JC; Heimark RL; Cress AE; Dickinson S; Stampfer MR; Futscher BW
PLoS One; 2010 Jan; 5(1):e8697. PubMed ID: 20084174
[TBL] [Abstract][Full Text] [Related]
17. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.
Chang CJ; Chao CH; Xia W; Yang JY; Xiong Y; Li CW; Yu WH; Rehman SK; Hsu JL; Lee HH; Liu M; Chen CT; Yu D; Hung MC
Nat Cell Biol; 2011 Mar; 13(3):317-23. PubMed ID: 21336307
[TBL] [Abstract][Full Text] [Related]
18. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
19. MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc.
Anastasiadou E; Messina E; Sanavia T; Mundo L; Farinella F; Lazzi S; Megiorni F; Ceccarelli S; Pontecorvi P; Marampon F; Di Gioia CRT; Perniola G; Panici PB; Leoncini L; Trivedi P; Lenzi A; Marchese C
Cells; 2021 Mar; 10(3):. PubMed ID: 33804458
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
